Company Overview - Metagenomi will reduce its workforce by 25% and change its CEO to extend its cash runway to Q4 2027, focusing on advancing its lead candidate MGX-001 for haemophilia A treatment [1][4] - The company has $184.1 million in marketable securities as of September 30, 2025, indicating a significant financial position despite recent challenges [4] Stock Performance - Following the announcement of layoffs and leadership changes, Metagenomi's shares fell 9% to $2 at market open on November 12, and closed down an additional 7% by the end of the day, reflecting investor concerns [2] - The company's market capitalization stands at $69.8 million, with stock prices having dropped over 80% since its IPO, which raised $93.75 million at a $15 stock price [2][5] Strategic Focus - The company is shifting its focus from early discovery and platform research to clinical testing of MGX-001, while also continuing development of its genome integration system for other disorders and pursuing partnerships for cardiometabolic disease treatments [1][3] - Newly appointed CEO Jian Irish emphasized commitment to programs with the highest probability of success and potential for near-term value creation [4] Market Context - Haemophilia A, the target condition for MGX-001, affects approximately 225,000 patients globally, with current treatments including factor VIII replacement therapy and innovative therapies like Roche's Hemlibra [7][8]